Dynamic PolyConjugates for targeted in vivo delivery of siRNA to hepatocytes
- David B. Rozema*,†,
- David L. Lewis*,†,
- Darren H. Wakefield*,
- So C. Wong*,
- Jason J. Klein*,
- Paula L. Roesch*,
- Stephanie L. Bertin*,
- Tom W. Reppen*,
- Qili Chu*,
- Andrei V. Blokhin*,
- James E. Hagstrom*, and
- Jon A. Wolff‡
- *Mirus Bio Corporation, 505 South Rosa Road, Madison, WI 53719; and
- ‡Departments of Pediatrics and Medical Genetics, Waisman Center, University of Wisconsin, 1500 Highland Avenue, Madison, WI 53719
-
Edited by Inder M. Verma, The Salk Institute for Biological Studies, La Jolla, CA, and approved June 18, 2007 (received for review April 24, 2007)
Abstract
Achieving efficient in vivo delivery of siRNA to the appropriate target cell would be a major advance in the use of RNAi in gene function studies and as a therapeutic modality. Hepatocytes, the key parenchymal cells of the liver, are a particularly attractive target cell type for siRNA delivery given their central role in several infectious and metabolic disorders. We have developed a vehicle for the delivery of siRNA to hepatocytes both in vitro and in vivo, which we have named siRNA Dynamic PolyConjugates. Key features of the Dynamic PolyConjugate technology include a membrane-active polymer, the ability to reversibly mask the activity of this polymer until it reaches the acidic environment of endosomes, and the ability to target this modified polymer and its siRNA cargo specifically to hepatocytes in vivo after simple, low-pressure i.v. injection. Using this delivery technology, we demonstrate effective knockdown of two endogenous genes in mouse liver: apolipoprotein B (apoB) and peroxisome proliferator-activated receptor alpha (ppara). Knockdown of apoB resulted in clear phenotypic changes that included a significant reduction in serum cholesterol and increased fat accumulation in the liver, consistent with the known functions of apoB. Knockdown of ppara also resulted in a phenotype consistent with its known function, although with less penetrance than observed in apoB knockdown mice. Analyses of serum liver enzyme and cytokine levels in treated mice indicated that the siRNA Dynamic PolyConjugate was nontoxic and well tolerated.
Footnotes
- †To whom correspondence may be addressed. E-mail: dave.rozema{at}mirusbio.com or dave.lewis{at}mirusbio.com
-
Author contributions: D.B.R. and D.L.L. contributed equally to this work; D.B.R., D.L.L., D.H.W., S.C.W., J.J.K., J.E.H., and J.A.W. designed research; D.H.W., S.C.W., J.J.K., P.L.R., S.L.B., T.W.R., and Q.C. performed research; A.V.B. contributed new reagents/analytic tools; D.B.R., S.C.W., and D.L.L. analyzed data; and D.B.R., D.L.L., and J.A.W. wrote the paper.
-
Conflict of interest statement: All of the authors except J.A.W. are employees of Mirus Bio.
-
This article is a PNAS Direct Submission.
-
This article contains supporting information online at www.pnas.org/cgi/content/full/0703778104/DC1.
- Abbreviations:
- CDM,
- carboxy dimethylmaleic anhydride;
- iNOP,
- interfering nanoparticle;
- NAG,
- N-acetylgalactosamine;
- SNALP,
- stable nucleic acid lipid particle.
- © 2007 by The National Academy of Sciences of the USA





